Newest recommendation of European Society of Cardiology for the diagnosis and treatment of heart failure – summary Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Nov 28, 2016
Keywords:
guidelines, ESC, 2016, Entresto, PARADIGM-HF

Main Article Content

Maciej Jelonek
Klinika Chorób Wewnętrznych, Nadciśnienia Tętniczego i Angiologii, Warszawski Uniwersytet Medyczny, Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie

Abstract

In this article we discuss major changes in diagnosis and treatment of heart failure that were published in European Society of Cardiology guidelines 2016. Special attention was given to neprilysin inhibitor and wider application of ivabradine.

Downloads

Download data is not yet available.

Article Details

How to Cite
Jelonek , M. (2016). Newest recommendation of European Society of Cardiology for the diagnosis and treatment of heart failure – summary. Cardiology in Practice, 10(2), 36-40. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1285
Issue
Vol 10 No 2 (2016)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Ponikowski P., Voors A.A., Anker S.D. et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016; 37: 2129-2200.
2. McMurray J.J.V., Packer M., Desai A.S. et al.: Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 2014; 371: 993-1004.
3. Swedberg K., Komajda M., Böhm M. et al.: Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). Eur. J. Heart Fail. 2010; 12: 75-81.
4. Steffel J., Robertson M., Singh J.P. et al.: The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Eur. Heart J. 2015; 36: 1983-1989.
5. Ruschitzka F., Abraham W.T., Singh J.P. et al.: Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N. Engl. J. Med. 2013; 369: 1395-1405.